Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients - Top-Institutions - MDSpire

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • By

  • Yasuo Imanishi

  • Takumi Imai

  • Hisako Fujii

  • Rei Aida

  • Yuki Nagata

  • Tetsuo Shoji

  • Shinichiro Kashiwagi

  • Tsutomu Takashima

  • Masanori Emoto

  • January 15, 2025

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Bone Metabolism
    • Endocrinology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Bone Biology
    • Endocrinology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Endocrinology
    • Oncology
    • Bone Health

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Oncology
    • Endocrinology
    • Bone Metabolism

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Medical Oncology
    • Endocrinology
    • Bone Health

Original Source(s)

Eldecalcitol Add-on to Risedronate Reduces Bone Loss From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients

  • by Yasuo Imanishi, Takumi Imai, Hisako Fujii, Rei Aida, Yuki Nagata, Tetsuo Shoji, Shinichiro Kashiwagi, Tsutomu Takashima, Masanori Emoto

  • January 15, 2025

Related Content

The role of gut microbiota in osteoporosis: underlying mechanisms, clinical associations, and emerging biomaterials

Restorative Management of Constriction and Spacing Following Arch Expansion

MiR-1a-3p/Fcgr4-dependent osteoclast activation regulates pathological bone loss